medigraphic.com
Órgano Oficial de la Asociación Mexicana de Hepatología

2018, Number 3

<< Back Next >>

Ann Hepatol 2018; 17 (3)

Direct Acting Antivirals Improve HCV Treatment Initiation and Adherence Among Underserved African Americans

Beck KR, Kim NJ, Khalili M

Language: English
References: 19
Page: 413-418
PDF size: 153.79 Kb.


ABSTRACT

Introduction and aim. Adherence to hepatitis C (HCV) care was suboptimal in the interferon era among underserved African Americans (AA), but adherence data in the era of direct acting antivirals (DAA) is lacking in this population. We aimed to evaluate the impact of DAA on HCV care in underserved AA. Material and methods. Clinical records of AAs undergoing HCV evaluation attending a safety net health system liver clinic were reviewed from 2006 to 2011 (pre-DAA), and January 1, 2014 to December 31, 2016 (post-DAA). Results. 291 patients were identified (129 pre-DAA, and 162 post-DAA). Median age was 58, 66% were male, 91% had HCV genotype 1, and 70% had fibrosis ≥ stage 2. Post-DAA patients were older (60 vs. 53 years; p ‹ 0.001), had higher rates of insurance (98% vs. 88%; p ‹ 0.001), liver fibrosis ≥ stage 2 (77% vs. 61%; p = 0.048), ≥ 2 medical comorbidities (19 vs. 0.8%; p ‹ 0.001), and median baseline log10 HCV RNA (6.07 vs. 5.81 IU/mL; p ‹ 0.001), but lower median ALT (46 vs. 62 U/L; p ‹ 0.001). Post-DAA, fewer patients were treatment ineligible (5.6% vs. 39%; p ‹ 0.001) and more initiated therapy (71% vs. 8.5%; ‹ 0.001), were adherent to HCV care (82% vs. 38%; p ‹ 0.001), and achieved cure (95.7% vs. 63.6%, p ‹ 0.001). Availability of DAA was independently associated with improved adherence to HCV care (OR 10.3, 95% CI 4.84-22.0). Conclusion. Availability of DAA is associated with increased treatment eligibility, initiation, adherence to HCV care, and cure in HCV-infected underserved AAs; highlighting the critical role of access to DAA in this population.


REFERENCES

  1. Denniston MM, Jiles RB, Drobeniuc J, Klevens RM, Ward JW, McQuillan GM, Holmberg SD. Chronic Hepatitis C Virus Infection in the United States, National Health and Nutrition Examination Survey 2003 to 2010. Ann Intern Med 2014; 160: 293-300.

  2. Razavi H, ElKhoury AC, Elbasha E, Estes C, Pasini K, Poynard T, Kumar R. Chronic hepatitis C disease burden and cost in the United States. Hepatology 2013; 57: 2164-70.

  3. Saab S, Jackson C, Nieto J, Francois F. Hepatitis C in African Americans. Am J Gastroenterol 2014; 109: 1576-84.

  4. Chak E, Talal AH, Sherman KE, Schiff ER, Saab S. Hepatitis C virus infection in USA: an estimate of true prevalence. Liver Int 2011; 31: 1090-101.

  5. Schaeffer S, Khalili M. Reasons for HCV non-treatment in underserved African Americans: Implications for treatment with new therapeutics. Ann Hepatol 2015; 14(2): 234-42.

  6. Brau N, Bini EJ, Currie S, Shen H, Schmidt WN, King PD, Ho SB, et al. Black patients with chronic hepatitis C have a lower sustained viral response rate than non-blacks with genotype 1, but the same with genotypes 2/3, and this is not explained by more frequent dose reductions of interferon and ribavirin. J Viral Hepat 2006; 13: 242-9.

  7. Conjeevaram HS, Fried MW, Jeffers LJ, Terrault NA, Wiley- Lucas TE, Afdhal N, Brown RS, et al. Peginterferon and ribavirin treatment in African American and Caucasian American patients with hepatitis C genotype 1. Gastroenterology 2006; 131: 470-7.

  8. Jeffers LJ, Cassidy W, Howell CD, Hu S, Reddy KR. Peginterferon alfa-2a (40 kd) and ribavirin for black American patients with chronic HCV genotype 1. Hepatology 2004; 39: 1702-8.

  9. Moyer, VA, U.S. Preventive Services Task Force. Screening for hepatitis C virus infection in adults: a U.S. Preventive Services Task Force recommendation statement. Ann Intern Med 2013; 159: 349-57.

  10. Blumenthal D. Health care coverage under the Affordable Care Act - A progress report. N Engl J Med 2014; 371: 275- 81.

  11. Surjadi M, Torreullas C, Ayala C, Yee HF Jr., Khalili M. Formal patient education improves patients' knowledge of hepatitis C in vulnerable populations. Dig Dis Sci 2011; 56: 213-9.

  12. Lubega S, Agbim U, Surjadi M, Mahoney M, Khalili M. Formal hepatitis C education enhances HCV care coordination, expedites HCV treatment and improves antiviral response. Liver Int 2013; 33: 999-1007.

  13. Poynard T, Morra R, Halfon P, Castera L, Ratziu V, Imbert- Bismut F, Naveau S, et al. Meta-analyses of FibroTest diagnostic value in chronic liver disease. BMC Gastroenterol 2007; 7(40).

  14. AASLD-IDSA HCV Guidance panel. Hepatitis C guidance: AASLD-IDSA recommendations for testing, man- aging, and treating adults infected with hepatitis C virus. Hepatology 2015; 62: 932-54

  15. Beck KB, Kim N, Khalili M. Sofosbuvir-containing regimens for chronic hepatitis C are successful in the safety-net population: A real world experience. Dig Dis Sci 2016; 61: 3602.

  16. Wilder JM, Jeffers LJ, Ravendhran N, Shiffman ML, Poulos J, Sulkowski MS, Gitlin N, et al. Safety and efficacy of ledipasvir- sofosbuvir in black patients with hepatitis C virus infection: A retrospective analysis of phase 3 data. Hepatology 2016; 63(2): 437-44.

  17. Feld JJ, Jacobson IM, Hezode C, Asselah T, Ruane PJ, Gruener N, Abergel A, et al. Sofosbuvir and Velpatasvir for HCV Genotype 1, 2,4, 5, and 6. N Engl J Med 2015; 373: 2599-607.

  18. Su F, Green PK, Berry K, Ioannou GN. The association between race/ethnicity and the effectiveness of direct antiviral agents for hepatitis C virus infection. Hepatology 2017; 65: 426-38.

  19. Pawlotsky JM. Hepatitis C Virus Resistance to Direct-Acting Antiviral Drugs in Interferon-free Regimens. Gastroenterology 2016; 151: 70-86.




2020     |     www.medigraphic.com